VV-GMCSF-Lact treatment was associated with a decreased proportion of malignant GL261 cells and CD8<sup>+</sup> T lymphocytes, while rhGM-CSF treatment increased proportions of MDSCs, macrophages, NK cells, and tumor-associated neutrophils. The gene discussed is CD8A; the disease is neoplasm.